Abstract：
UNASSIGNED: Atopic dermatitis (AD) is an inflammatory skin condition that affects millions of pediatric and adult patients with well-studied impact on morbidity and quality of life. Management occurs in a stepwise fashion beginning with preventative measures before immunomodulators are introduced. However, challenges remain in treatment of moderate-to-severe atopic dermatitis that is refractory to first- and second-line treatments and there are only few topical anti-inflammatory options, especially for pediatric patients.
UNASSIGNED: New medications are required to address these gaps as lesions may persist despite treatment or patients may discontinue treatment due to actual or anticipated adverse effects of mainstay medications. Emerging research into the pathophysiology of AD and the immune system at large has provided opportunities for novel interventions aimed at stopping AD mechanisms at new checkpoints. Clinical trials for 36 agents currently in phase 2 or phase 3 are evaluated with particular focus on the studies for, B244, CBP-201, tapinarof, lebrikizumab, nemolizumab, amlitelimab, and rocatinlimab as they explore novel pathways and have some of the most promising results.
UNASSIGNED: These clinical trials contribute to the evolution of AD treatment toward greater precision based on salient pathways with a particular focus on moderate-to-severe AD to enhance efficacy and minimize adverse effects.
UNASSIGNED: New medications are required to address these gaps as lesions may persist despite treatment or patients may discontinue treatment due to actual or anticipated adverse effects of mainstay medications. Emerging research into the pathophysiology of AD and the immune system at large has provided opportunities for novel interventions aimed at stopping AD mechanisms at new checkpoints. Clinical trials for 36 agents currently in phase 2 or phase 3 are evaluated with particular focus on the studies for, B244, CBP-201, tapinarof, lebrikizumab, nemolizumab, amlitelimab, and rocatinlimab as they explore novel pathways and have some of the most promising results.
UNASSIGNED: These clinical trials contribute to the evolution of AD treatment toward greater precision based on salient pathways with a particular focus on moderate-to-severe AD to enhance efficacy and minimize adverse effects.
摘要：
■特应性皮炎（AD）是一种炎性皮肤病，影响数百万儿童和成人患者，对发病率和生活质量的影响已得到充分研究。在引入免疫调节剂之前，从预防措施开始逐步进行管理。然而,在一线和二线治疗难以治疗的中度至重度特应性皮炎的治疗中仍然存在挑战，并且只有很少的局部抗炎选择，尤其是儿科患者。
■需要新的药物来解决这些差距，因为尽管治疗，病变可能会持续存在，或者患者可能由于主要药物的实际或预期不良反应而停止治疗。对AD和整个免疫系统的病理生理学的新兴研究为旨在在新检查点停止AD机制的新型干预提供了机会。对目前处于2期或3期的36种药物的临床试验进行了评估，B244,CBP-201,Tapinarof,Lebrikizumab,尼莫珠单抗，Amlitelimab,和Rocatinlimab，因为他们探索新的途径，并有一些最有希望的结果。
■这些临床试验有助于AD治疗朝着基于显著途径的更高精确度发展，特别关注中度至重度AD，以提高疗效并最大限度地减少不良反应。
■需要新的药物来解决这些差距，因为尽管治疗，病变可能会持续存在，或者患者可能由于主要药物的实际或预期不良反应而停止治疗。对AD和整个免疫系统的病理生理学的新兴研究为旨在在新检查点停止AD机制的新型干预提供了机会。对目前处于2期或3期的36种药物的临床试验进行了评估，B244,CBP-201,Tapinarof,Lebrikizumab,尼莫珠单抗，Amlitelimab,和Rocatinlimab，因为他们探索新的途径，并有一些最有希望的结果。
■这些临床试验有助于AD治疗朝着基于显著途径的更高精确度发展，特别关注中度至重度AD，以提高疗效并最大限度地减少不良反应。
